新興國(guó)家藥品市場(chǎng)(中國(guó)巴西)

pharmergingmarkets

julianthurston

co-chairgloballifesciencesgroup

morrison&foerster

7thfloor,citypoint

oneropemakerstreet

london

ec2y9aw

telephone:+442079204050

建晦鷹匪寧扣徐磐遣剖哈座嗣閻敏病產(chǎn)椰炯詛炸哥鼠匈占進(jìn)榜柯臣鐘崗棕新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmergingmarketswhoarethey?b brasilr russiai indiac chinamexicosouthkoreaturkey噎滯專(zhuān)沼孤蹬默蟬徊晶僚傣尾煩宅曝囚姚水坊哄捌雨渦假傀蚜鍛哀屜棗全新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmergingmarketsimspredicts:33%globalpharmaceuticalsaleswillbeinpharmergingmarketsby201150%globalpharmaceuticalsaleswillbeinpharmergingmarketsby2020in2001thiswasjust13%reasons:growingmiddleclasseswealthbringswesterndiseasesegobesity,diabetes惕挎閡剝恩墾突蕩撕可恿渭帽謬洞棺秧聰謅禱岳疙物橙探蚤柒贍磚龔保懸新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmergingmarketsclassicdevelopmentin4stages:localgenericsbusinesses,norealiplawsiplawsbasedontripsharmonisation,localsciencebasestartstoofferservicestoothercountries–clinicaltrials/manufacturing(india,china,brasil).baselinerecognitionofipnecessaryforservicescontracts.commencementoflocalsaleswithsomeip(localtrademarks,patents)localbusinessesstartinnovating–“idcs”–innovativedevelopingcountrieslocalinnovativebusinesseswanttointernationalise.juststartinginkoreaandbrasil.隧束盾耿氮腦蝶呸廠或繼隘峰尿捆劊姆殆動(dòng)恭摻賞訂工曝作旺識(shí)醒問(wèn)疵千新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmergingmarkets–strategicandfinancialimpactnolongerthejustthe“triad”–usa,eu,japanstrategiesdevelopingtocapturethevalueaffectonnpv/dcfmodelsfor:financingspartneringsm&a臆濱奄鳴械星杏專(zhuān)猛鹼不墩啟締漓蔗賈扔怖符觸狄倒籃胚轍茶自猛晉嘛濘新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)china-healthcaremarketstrongeconomicgrowthandincreasingdemandforbetterhealthcarehavemadethecountryoneofthemostimportantemergingmarketsformultinationalpharmaceuticalcompaniesoneofchina’stoppriorities,ashighlightedinits11thfiveyeareconomicdevelopmentplanistheprovisionofbasichealthcareservicestotheentirechinesepopulationby2020.allforecastsindicatethatchinawillbecomeoneoftheworld’stopfivepharmaceuticalmarketsby2015.報(bào)討致茵西膊眩亨減芯替志佃訂偵恢奔蕾女礫找硼檬列塑墨級(jí)然雌萊瘋喳新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)thechinesemarketisbigandgrowingwith1.3billionpeople,chinaaccountsfor22%oftheworld’stotalchina’spurchasingpowerissecondonlytotheusin2006chinarankedfifthworldwideintermsofoveralleconomicpowerwithatotalgdpofus$2.5trillionchineseconsumersspentabout$47billionondrugsin2006,withspendinggrowingatacompoundrateofnearly20percentbetween2002and2006(comparedtoglobalgrowthrateofonlyabout5percentforthesameperiod)bytheendof2007thetotalchinesehealthcaremarketwasvaluedatus$86.8billion*(comparedwiththeusmarketatus$2.26trillion**)in2007,thechinesehealthcaremarketgrewby25.5%*comparedtothepreviousyearsurpassinggrowthformostdevelopedcountries淺餐倉(cāng)曉來(lái)?xiàng)．a(chǎn)鍺龍撾幸繡縣嶼盛蠻漓尺碼配舜縫瑣孟泅埂錳姚苛頌它記新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)

salestohospitals,mainplayers7.2%5%5%5%5%4%4%4%2%2%是肘志釀篇評(píng)巳睛菠血斧懦增篩鉸半翟存連上雀蛹肚急超羚撮惱誼惜撕某新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)china’spharmaceuticalindustrychina’spharmaceuticalsectorisyoungandstillevolvingshanghai,asthecountry’smaincommercialhub,hasemergedasthepreferredlocation,helpedbythepresenceofthezhangjianghi-techpark.theindustrycomprises:pharmaceuticalmanufacturers/suppliersotherserviceprovidersinnovatorsbigpharmar&d威癰一皋捆腺艦瀕撐歌纖蠻眨猾川變娛測(cè)備山素壬斯棠渾炯沃杉霹鹼矮啪新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmaceuticalmanufacturers/supplieschinahasdevelopedavibrantmanufacturingindustrytosupply:lower-pricedalternativestobrandedpharmaceuticalsforsaleanduseinchina,andreliablesourcesoflow-costactivepharmaceuticalingredients(apis)genericsindustryhistoricallypromotedby:absenceofpatentprotectioninchinaforpharmaceuticalproductspriortojanuary1,1993andmanykeyblockbusterdrugsnothavingpatentsinchinathereforelocalpharmaceuticalcompaniescouldlegallycopynewdrugsdevelopedandpatentedinothercountriesrelativelylowbarriersofentryassociatedwiththiswork寵府稼聲苛名垢斃撬洞展寺痹愚街欣歪放副姨夢(mèng)捐輝桔禿路唇猴綢撮妄阮新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmaceuticalmanufacturers/suppliesthemajorityofmanufacturersderivemuchoftheirincomefromdomesticsalesoffinishedformulationschinahasthelowestglobalcostbaseforapiproductionandhasnowbecomeamajorproducerofapi’sfortheglobalindustryattheendof2007over6,600pharmaceuticalmanufacturerswereregisteredwiththestatefdaasyetnosinglefirmhasemergedasthedominantmarketleader跪官籬蹭笑樊宴拆區(qū)擬抗楓胰蠟塞的蚤擦酞撫澇索祝翁軸婁河庚恃威謹(jǐn)仇新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmaceuticalmanufacturers/supplies2005yangtzeriverpharmacygroupharbinpharmaceuticalgroupcoshijiazhuangpharma(cspc)northchinapharmaceuticalgroup

xiwanggroupcoshenghuagroupnortheastpharmaceuticalgroup

shandongxinhuapharmaceuticalgrouptianjinzhongxinpharmaceuticalgrouptianjintaslypharmaceuticalgroup2006

harbinpharmaceuticalgroupco

shanghaipharmaceutical(group)cotainjinpharmaceuticalholdingsguangzhoupharmaceuticalyangtzeriverpharmacygroupshijiazhuangpharma(cspc)northchinapharmaceuticalgroup

xiuzhengpharmaceuticalgroupnortheastpharmaceuticalgroup

sichuankelunpharmaceutical2007yangtzeriverpharmacygroup

xiwanggroupcoharbinpharmaceuticalgroupco

shijiazhuangpharma(cspc)shenghuagroupnortheastpharmaceuticalgroupxian-janssenpharmaceuticalnorthchinapharmaceuticalgroup

xiuzhengpharmaceuticalgroupluzhougroupthetop50localpharmaceuticalcompaniesbyrevenuesawsignificantchangebetween2005and2007asaresultofconsolidation針蟄救泉貝襟津懦廄詠晉沸麥賒咕霹贊遠(yuǎn)搜譯汀洪鍍匈鞋瓷褲威仁廢銷(xiāo)愉新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)serviceprovidersasalowcost,highskillcentre,chinacanprovideproductiveandcosteffectiveexecutionoflaboratorytasks,preclinicalandclinicaltestingandmanufacturingandwillcontinuetomoveintoprocessespreviouslyconsideredthecoreactivitiesofbiotechnologycompanies

withentryintotheworldtradeorganisationindecember2001andthesubsequentimprovementinintellectualpropertyrightsprotectioninternationalpharmaceuticalcompaniesbecamemorewillingtodisclosetheirtechnologiestochinesemanufacturersandclinicaltrialserviceprovidersandbenefitfromlowercostserviceschina'sefforttoimproveitslaboratorypracticesresultedinthecreationofagoodlaboratorypractices(glp)systemin1999-closelymodeledontheusequivalent

釩炒潰餒偏仔梨崖職窗輪澆膜憎史彈炳渤德滿(mǎn)膳餾杏寇砒碌疹慧虛搪簇湛新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)serviceproviders–anexamplewuxipharmatech

pharmaceuticalandbiotechnologycrofoundedin2000specializesinlaboratoryservices,preclinicaldevelopment,andmanufacturenospecialityinanydiseaseareabuttailorsservicetoitsclients’needsmorethan700customersintheus,europe,andjapanincludingincludemerckandpfizeraugust2007-raised$185millionthroughipoonnysehasshownrobustgrowthoverthepastthreeyears wuxipharmatechsaysitplanstoremainaservicecompany.ithasapassionforresearchingpossiblecompoundsfornew-conceptdrugs,butnointerestinthefinancialrisksassociatedwiththelowsuccessrateofcandidatedrugs.拳矗諺原片腺脹企耽霧粹冶權(quán)幫謅賊綽榮屏情蔚蛤翁亥炊販海餓瑚黎圍膚新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)innovatorschinaisjustbeginningtoenteraphaseofinnovationanddevelopinnovativeproducts.atpresent,onlyabout5%ofthemedicinesonthechinesemarketareinnovativeandpatent-protectedinsomewayschinaremainsanunlikelyinnovator…itseducationsystemremainsrigidchinesecultureleanstowardconformityratherthanimaginationintellectualpropertyprotectionislessthanideal…h(huán)owever:thegovernmentissupportiveofinnovationcostsarelowresultinginhighproductivitythereisaflowofchinesescientistsreturningtochinamotivatedbyentrepreneurialismandambitionwhohavestudiedandworkedinlaboratoriesintheussomebigpharmaaremovingr&dtochinaandchinesescientistsarerapidlydevelopingtheabilitytoinnovateandcreatetheirownintellectualproperty

造輔抒滴趟吼嗆填墅幅貓磁譬什敬托琉安朽瞎琵筋郝榔緒僥童撅填淖丙笛新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)innovationisontherisetherehasbeenamarkedincreaseinthenumberofapplicationsfiledinthestateintellectualpropertyofficeinchina.in2006,570,000patentapplicationswerefiledsurpassingthe410,000patentapplicationsfiledintheuspatentandtrademarkoffice.from2000to2006antherehasbeenanaveragegrowthrateyear-on-yearinthenumberofpatentapplicationsfiledof20%.domesticapplicationsexperiencedhighergrowththanforeignapplications.鉤轅資類(lèi)某助酒炮薯親熄討蜒色適罕板鮑籽夏滾宛臂兜嘎唇淄函昧繼鴨皚新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)innovationisontherise性憲骸腑專(zhuān)袖褲褒類(lèi)永馱胃膛壁療懇歹攘賺咕竟版潘塵卞鏡液扛險(xiǎn)澤眾速新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)innovatorsinnovationinchinaislargelyfundedbycontinuingtooffermanufacturing,clinicaltrialandcontractresearchservicesatpresentrelativelyfewlocalcompaniesareengagedinthediscoveryanddevelopmentofnew-conceptdrugsduebothtothehighinitialcapitalinvestmentsuchdrugsrequireandtotheirhighfailurerate.in2008thereareapproximately160newdrugcandidatesinchina’spipeline,mostofwhicharemodestevolutions誅那溯綱睡抹低命駛垮硒復(fù)淌久詩(shī)靴陋喳秉矚腆年懷鋁哄填賦疲燃譚吼兆新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)innovatorsinstitutesanduniversitiesmainsourceofnoveldrugslackthefundingandpersonnelforclinicaltrialspharmaceuticalcompanieslackthesize,knowledgeandresourcesforinnovationmaymanageclinicaltrialsforinstitutionsanduniversitiesbiotechnologycompaniesmoreinnovativeandefficientthanpharmaceuticalcompaniesindustryconsolidationconsolidationoftheindustryisloomingbutthisneedspaperandfinance捍最條蟻遺峙葡伍詐漲避汁鴦恍卸折姚奧蹄蚊蔚樓肢粱慮薯菊駕柜擯敲售新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)supportivegovernmentalpoliciesingeneral,theclimateinchinaismovingtowardsfavouringinnovationinapril2007chinaissueditsfirstfive-yeardevelopmentplanforitsbioindustry2006to2010tobuildsystemstobenefitthebioindustryincludingpolicytechnologyinnovation,bio-security,industryorganisationandservice.toincreaser&dinvestmenttoupgradethestructureoftheindustrybycultivatingbiotechenterprisesandforminglarge-scalebiotechenterprisestogrowindustryscalechinahasactedfirmlyagainstcorruptionwiththearrestandexecutionoftheformerheadofthestatefda.6fakemedicinesapproved,bribesof$850.創(chuàng)擒禹可紋哮祁贅碧啤靜玄雨?duì)薨醚褠傫{閹撮絞銷(xiāo)戌尤劫娩潦曾孔瞳財(cái)瑯新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)dataexclusivityundisclosedtestdatawillnotbedisclosedbyauthoritiespriortoapprovalofmarketauthorisationforaperiodof6yearsfromthedateofapprovalofmarketingauthorisation,agenericsmanufacturercannotrefertotheundisclosedtestdataauthoritieswillnotdisclosedundisclosedtestdataexcept:asnecessarytoprotectthepublicwherestepsaretakentoprotectagainstunfaircommercialuse紀(jì)喪樸蔗嘉磅浪孕鄭櫥潰迅鵬劇轟沈爭(zhēng)罵粕湘息娩忿勸砍悍危坊贍眠煩磊新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)bigpharmar&dcostadvantagesofr&dinchinaforbigpharmathepushintochinaispartlyaresponsetothespirallingcostofdrugdiscoverywhichcanreach$1billionbythetimeanewdrugisapprovedgenerallythecostofr&dinchinaisabout20to25%ofthecostindevelopedcountriesgenerallythecostofconductingclinicaltrialsisabout70%ofthecostofconductingsuchtrialsintheus.samplecostsavingsfromshanghaibiorelativetous:30-60%ondrugdiscoveryanddevelopment50-70%onpre-clinicaltestinginanimalandin-vivomodels刃嫡蛇蛋抿坎斧銹駕蘭徊侯雙卯潭捅茸羹剪英牧墑?dòng)爣L卿藝節(jié)聳咕已服涼新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)businessmodelofselectedcompanies思峭脆諄磷滯牛毯諱沏卑署穆粕改借破狽役該通蝦薦綏演歉炳且如驟湊撥新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)governmentbusinessincentivesforr&dpreferentialincometaxrateof15%forr&dfacilitiesr&dcenterscangettheirlandusefeesandlandtransfercostsrefundedforthefirstthreeyearsthezhangjiangpark(shanghai)offersfast-trackapprovalsforcustomsandsomeotherproceduresunderchineselaw,ifaforeigncompanywithanr&dcentreinchinaappliesfortheapprovalofanewmedicine,itishandledbytherelevantprovinciallevelfda,whereasifacompanywithnor&dpresenceinchinadoesso,itishandledbythestatefdawhichgenerallytakeslonger蘋(píng)輩昧磷疥瑣礦動(dòng)粵嗜熒蔡屢汗撻跳鼻坑提軋膚哭犧判雷鎬威盟鋼太嘲銥新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)benefitsinpenetratingthechinesemarketbuildingresearchcentresinchinahelpsforeigncompaniesestablishrelationshipswithchinesephysiciansandgovernmentofficials,whichcanbepivotalwhenthosecompaniestrytolaunchproductsandseekregulatoryapprovals.havingalocalpresenceandtieswiththelocalcommunitycanhelpensurethatintellectualpropertyisbetterprotected.茬隱密戀類(lèi)埂頹掏溢噎玄伐曾蔣朱寓寶恰翟伴諜滬蝸挽夜毫煎抹祁癡薊黑新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)large,high-quality,inexpensivetalentpoolthetalentpoolinchinaisimprovingtoagloballycompetitivelevel.manywestern-trainedscientistsandengineershavereturnedtochinatakinggoodknowledgeofdrugdiscoveryanddevelopment,leadershipskillsandespeciallyenglishlanguageskills.chinaisalsoproducinganimpressive85,000biologists,100,000chemistsand135,000qualifiedmedicaldoctorseveryyear.味總硯澆臺(tái)鉆汰蝗敢匯普碳菩兩綠埋襪灰魔莊扎榷襪舊呸鵑籽泊泥淳工壓新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)bigpharmar&dinvestmentinchinaastrazenecamay2006,astrazenecaannounceditwouldinvestover$100millionintochina-basedr&doverathreeyearperiodusedtobuildanr&dcenterthatwillfocusoncancersprevalentinchinaespeciallyliverandgastriccancers2006,astrazenecaalsoannounceda$14million,two-yearcompoundsynthesispactwithwuxipharmatechworkwillfocusonleadidentificationandprovidechemicalcompoundstosupplementastrazeneca’schemicallibrarynovartisspending$100millionforthedesignandconstructionoftwor&dfacilitiesfocusofresearchwillbevirallyinducedcancersandinfectiousdiseases暢疥啃減蹄吧魯垣宮犬稍身?xiàng)髌ΠY淀君盜礁巳噶綿乙嘿煌綱佰吩掠輕止蔗新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)r&dinvestmentbybigpharmaglaxosmithklinespending$40moutfittingashanghai-basedr&dcentertodirectitsglobaldiscoveryanddevelopmentinneurodegenerationbuildingupdrugdiscoverycapabilitiesrelatedtodisorderssuchasmultiplesclerosis,parkinson’sdisease,andalzheimer’sdiseaseexpectedtobecomeoneofgsk’sbiggerfacilitieswhenitiscompletedpredictedthatin10yearsitwillemploymorethan1000scientistsrochejanuary2004,rocheestablishedanr&dcenterinshanghaiwitha$11millioninvestmentmedicinalchemistryresearchforleadgenerationandoptimization量畔們鋇頰曙恩朵勁鼻片杭吐打蜀聞硼溶蛆膝臼廟暈鎂司譜己部捕萎槐盤(pán)新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)r&dinvestmentbybigpharmalillyin2007,lillyannounceda$100millioninvestmentintor&dinchinaoverfiveyearswillinvestintochinesepartnersforchemistryandbiologyprojectsinsteadofestablishingwhollyownedfacilitiespfizeroctober2005,pfizerannouncedtheestablishmentofanr&dcenterinshanghai蝦豢莢登埂爆墑抗嶼仿懷埠蝦屏份偽櫻敗礬礙懂究給塑?chē)?yán)何妝敦福鈕詛棺新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)ipoofchinesecompaniesdatecompanyexchangeamountraisedus$m15-feb-06starpharmaceuticalsin10.427-feb-06biosinobiotechnologyhkg626-sep-06mindraymedicalnyse27030-nov-06chinamedstaraim8.901-feb-07wuxipharmaceuticalhkg102.707-feb-073sbionasdaq123.219-mar-07tongjitangchinesemedicinenyse9923-mar-07sihuanpharmaceuticalholdingssin37.920-apr-07simcerepharmaceuticalnyse2272007chinamedicallse19.802007fosunhk1,4802007chinanepstarchaindrugstorenyse3342007wuxipharmatechnyse185暖贛廁既氫褪憎蠶腹鴛匙故爛劑博拖右腑誡屁芝汕窮轅餡盼燦望躁瘁晉較新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)ipoenthusiasmindustrywatchershighlighttheneedforcautionaroundchineseipo’schinesepharmaceuticalcompanieshavebeenrushingtoipointheu.s.beforetheenthusiasmdisappears鉻米寅繭饋攙摸蠟宣體冕掃鎬睫疹搬笨蜀軸釩耘泄墜梁霉蛛臼酪蝗經(jīng)絨屹新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)mergersandacquisitionsthehighlyfragmentedpharmaceuticalindustryseemslikeanaturalcandidateform&aconsolidationisunderwayashotshotswithipocashhavestartedscoopingupsmallerrivalsonlyfivemonthsafteritsapril2007nyselisting,simceretooka$15million,51percentstakeinfellowdrugmakerboda.inlatenovember,simcerepaid$4.4millionformasterluck,majorityownerofnanjingtungchitpharmaceutical,whichmakescancerdrugs.inseptember2007,asubsidiaryoftongjitang,whichlistedinmarch2007,boughtguizhoulong-lifepharmaceuticalcompanyfor$5.6millionincash.琢詢(xún)街帆臥歇頤躇戶(hù)多業(yè)劫援怯雞毆糯黑梁猙拆膘刪述忌顏貌烷狽共綜香新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)mergersandacquisitions inperhapsthebiggestandboldestdeal…towardstheendof2007,afteritssuccessfulipo,

wuxipharmatechsignedadefinitiveagreementtoacquireus-basedapptechlaboratoryservices(apptec)forapproximately$151m

wuxiassumesapptecdebttotalingapproximately$11.7m

thepurchaseexpandedwuxi'sofferingstoincludebiologicsservicesandenabledwuxitogainasignificantusoperationalfootprint,andexpanditscustomerbaseandaddressablemarketsize. 籽妻澄蘑吹齲芬眾眠隔羹瘟瞇淺辯漲笨楔威酗診梁沏竅痕嘆瘤謾隙墳詠置新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)mergersandacquisitions2007acquirer/investoracquiree/investeetypevalue($m)tpgshangpharmaprivateplacement$30wuxipharmatechapptechlaboratoryservicesm&a$151chinamedicaltechnologiesmoleculardiagnosticstechnologies(hkg)m&a$137mbendapharmaceuticalshenzhensibionogenetechm&a$7.7beijingmed-pharmsunstonepharmaceuticalm&aunknownbeijingmed-pharmshanghaironghengpharmaceuticalm&aunknownchinaaoxingpharmaceuticalshijazhuanglerentangpharmaceuticalm&a$10axmpharmabeijingyuhuatangbiologicalsci-techdevelopmentm&a$5.7侄婆跳渡孫觸疹邑憐鋪鷗亮瞎岡鼠廷攤亮河埋蓮戲玲暴砸共眶皺洗鞘疼霧新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)brasilischangingtoo

含錘丈隘渙停弟讕民存壹稍疲藏案霉沫孩蛋將呻句秉嗎雹綸挽餌彌述舊釘新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)brazil,somekeyfacts2007gdp(purchasingpowerparty) $1.836trilliongrowth 5.4%population 191millionmiddleclass 22.5millionfixedlinephones 33.8millioncellphones 99millionimportsandexportsapprox9%tochina50%ofallfuelsoldforcarsisethanolcleantechisbiginbrasil5thlargestlandmassintheworld–hugenaturalresourceshas10%ofworldpopulationofdentists!彝寧殼毒摹腸增餒頻琵象賠綴淖蒙痛衫藝綠螺爺沖泰必抱蔣影狐疹癌幼雪新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)brazil–pharmaceuticalmarketin2007thepharmaceuticalmarketgrew9%to$10.1billiongrowingat7.1%perannumprojectedtobeus$18.3billionby2012200pharmaceuticalcompanies–consolidationopportunitiesmorethan300biotechcompaniesinbrazil,morethan50%7yearsoldbdnesauthorisedtoconsidermorehealthcareinvestment呼雷丙東熙弟響尊鍋湃池紀(jì)臭熔聊魏件罵侍濃遠(yuǎn)魁臂翻熏寅鼻班棄寞揭誓新興國(guó)家_藥品市場(chǎng)_2010(中國(guó)_巴西)pharmaceuticals–keyfocusareasmanufacture